PONATINIB, PONATINIB, Ponatinib, IMATINIB, IMATINIB
Ponatinib-3001
Phase 3 small_molecule active
Quick answer
PONATINIB, PONATINIB, Ponatinib, IMATINIB, IMATINIB for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active